IMMEDIATE SUPPRESSIVE VS EPISODIC THERAPY FOLLOWING NEONATAL HERPES SIMPLEX

新生儿单纯疱疹后的立即抑制治疗与间歇性治疗

• 批准号: 6263427
• 负责人: DAVID W KIMBERLIN
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6263427
• 关键词: Alphaherpesvirinae; Herpes simplex disease; acyclovir; clinical research; human subject; human therapy evaluation; microorganism disease chemotherapy; newborn human (0-6 weeks); oral administration

This protocol evaluates the use of six months suppressive oral acyclovir therapy in neonates following herpes simplex virus disease limited to the skin, eye, and mouth. This is a double-blind, randomized study. Following 14 days of IV acyclovir, neonates will be randomized to receive suppressive acyclovir or to receive identically flavored placebo for a period of six months. Cutaneous HSV recurrences in either group will be treated with open label oral acyclovir.

本方案评估在新生儿单纯疱疹病毒病局限于皮肤、眼睛和口腔后6个月口服无环鸟苷抑制治疗的使用。这是一项双盲随机研究。在14天静脉注射阿昔洛韦后，新生儿将被随机分配接受抑止性阿昔洛韦或接受相同口味的安慰剂，为期6个月。两组的皮肤HSV复发均采用开放标签口服阿昔洛韦治疗。